Cargando…
Acquired lymphedema: Molecular contributors and future directions for developing intervention strategies
Lymphedema is a debilitating chronic disease that mostly develops as an adverse reaction to cancer treatment modalities such as chemotherapy, surgery, and radiotherapy. Lymphedema also appears to be a deteriorating consequence of roundworm infections, as best represented by filariasis. According to...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9640931/ https://www.ncbi.nlm.nih.gov/pubmed/36386144 http://dx.doi.org/10.3389/fphar.2022.873650 |
_version_ | 1784825974264692736 |
---|---|
author | Nurlaila, Ika Roh, Kangsan Yeom, Chang-Hwan Kang, Hee Lee, Sukchan |
author_facet | Nurlaila, Ika Roh, Kangsan Yeom, Chang-Hwan Kang, Hee Lee, Sukchan |
author_sort | Nurlaila, Ika |
collection | PubMed |
description | Lymphedema is a debilitating chronic disease that mostly develops as an adverse reaction to cancer treatment modalities such as chemotherapy, surgery, and radiotherapy. Lymphedema also appears to be a deteriorating consequence of roundworm infections, as best represented by filariasis. According to its origin, lymphedema is classified as primary lymphedema and acquired lymphedema. The latter is an acquired condition that, hitherto, received a considerably low attention owing to the less number of fatal cases been reported. Notably, despite the low mortality rate in lymphedema, it has been widely reported to reduce the disease-free survival and thus the quality of life of affected patients. Hence, in this review, we focused on acquired lymphedema and orchestration of molecular interplays associated with either stimulation or inhibition of lymphedema development that were, in vast majority, clearly depicted in animal models with their specific and distinct technical approaches. We also discussed some recent progress made in phytochemical-based anti-lymphedema intervention strategies and the specific mechanisms underlying their anti-lymphedema properties. This review is crucial to understand not only the comprehensive aspects of the disease but also the future directions of the intervention strategies that can address the quality of life of affected patients rather than alleviating apparent symptoms only. |
format | Online Article Text |
id | pubmed-9640931 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-96409312022-11-15 Acquired lymphedema: Molecular contributors and future directions for developing intervention strategies Nurlaila, Ika Roh, Kangsan Yeom, Chang-Hwan Kang, Hee Lee, Sukchan Front Pharmacol Pharmacology Lymphedema is a debilitating chronic disease that mostly develops as an adverse reaction to cancer treatment modalities such as chemotherapy, surgery, and radiotherapy. Lymphedema also appears to be a deteriorating consequence of roundworm infections, as best represented by filariasis. According to its origin, lymphedema is classified as primary lymphedema and acquired lymphedema. The latter is an acquired condition that, hitherto, received a considerably low attention owing to the less number of fatal cases been reported. Notably, despite the low mortality rate in lymphedema, it has been widely reported to reduce the disease-free survival and thus the quality of life of affected patients. Hence, in this review, we focused on acquired lymphedema and orchestration of molecular interplays associated with either stimulation or inhibition of lymphedema development that were, in vast majority, clearly depicted in animal models with their specific and distinct technical approaches. We also discussed some recent progress made in phytochemical-based anti-lymphedema intervention strategies and the specific mechanisms underlying their anti-lymphedema properties. This review is crucial to understand not only the comprehensive aspects of the disease but also the future directions of the intervention strategies that can address the quality of life of affected patients rather than alleviating apparent symptoms only. Frontiers Media S.A. 2022-10-25 /pmc/articles/PMC9640931/ /pubmed/36386144 http://dx.doi.org/10.3389/fphar.2022.873650 Text en Copyright © 2022 Nurlaila, Roh, Yeom, Kang and Lee. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Nurlaila, Ika Roh, Kangsan Yeom, Chang-Hwan Kang, Hee Lee, Sukchan Acquired lymphedema: Molecular contributors and future directions for developing intervention strategies |
title | Acquired lymphedema: Molecular contributors and future directions for developing intervention strategies |
title_full | Acquired lymphedema: Molecular contributors and future directions for developing intervention strategies |
title_fullStr | Acquired lymphedema: Molecular contributors and future directions for developing intervention strategies |
title_full_unstemmed | Acquired lymphedema: Molecular contributors and future directions for developing intervention strategies |
title_short | Acquired lymphedema: Molecular contributors and future directions for developing intervention strategies |
title_sort | acquired lymphedema: molecular contributors and future directions for developing intervention strategies |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9640931/ https://www.ncbi.nlm.nih.gov/pubmed/36386144 http://dx.doi.org/10.3389/fphar.2022.873650 |
work_keys_str_mv | AT nurlailaika acquiredlymphedemamolecularcontributorsandfuturedirectionsfordevelopinginterventionstrategies AT rohkangsan acquiredlymphedemamolecularcontributorsandfuturedirectionsfordevelopinginterventionstrategies AT yeomchanghwan acquiredlymphedemamolecularcontributorsandfuturedirectionsfordevelopinginterventionstrategies AT kanghee acquiredlymphedemamolecularcontributorsandfuturedirectionsfordevelopinginterventionstrategies AT leesukchan acquiredlymphedemamolecularcontributorsandfuturedirectionsfordevelopinginterventionstrategies |